Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 6/20 | 0.49 |
| ▸ | MMP2 | P08253 | 4/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.46 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.46 |
| ▸ | MMP1 | P03956 | 1/20 | 0.46 |
| ▸ | MMP9 | P14780 | 1/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.44 |
| ▸ | MMP12 | P39900 | 1/20 | 0.44 |
| ▸ | LIPE | Q05469 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6097329 | 0.91 | MMP13 (0.49) | MMP13MMP2MMP1MMP9ADAM17 | |
| SCHEMBL6096620 | 0.91 | ADRB2 (0.52) | ADRB2MMP13MMP2KCNH2SLC6A5 | |
| SCHEMBL6096396 | 0.90 | ADRB2 (0.54) | ADRB2MMP13MMP2MMP1MMP9 | |
| Hydrochloric Acid SCHEMBL6097341 | 0.89 | ADRB2 (0.53) | ADRB2MMP13MMP2MMP1MMP9 | |
| SCHEMBL6099760 | 0.86 | MMP13 (0.48) | ADRB2MMP13MMP2KCNH2CACNA1G | |
| SCHEMBL6099484 | 0.83 | MMP13 (0.49) | ADRB2MMP13MMP2MMP1MMP9 | |
| SCHEMBL6098660 | 0.82 | ADRB2 (0.48) | ADRB2MMP13MMP2KCNH2MMP1 | |
| SCHEMBL6096440 | 0.82 | MMP13 (0.49) | MMP13MMP2MMP1MMP9MMP12 | |
| SCHEMBL6097350 | 0.82 | MMP13 (0.47) | MMP13MMP2KCNH2MMP9MMP12 | |
| SCHEMBL6095774 | 0.81 | MMP1 (0.54) | MMP13MMP2MMP1MMP9ADAM17 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7067670-B2 | Sulfamato hydroxamic acid metalloprotease inhibitor | WARNER LAMBERT COMPANY (US) | 2006-06-27 | — | — | US | disclosed |
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2005-03-03 | — | — | US | disclosed |
| US-6800646-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | PHARMACIA CORPORATION | 2004-10-05 | — | — | US | disclosed |
| US-6492367-B1 | Sulfamato hydroxamic acid metalloprotease inhibitor | G. D. SEARLE & COMPANY | 2002-12-10 | — | — | US | disclosed |
| US-6448250-B1 | INHIBITS THE ACTIVITY OF ONE OR MORE OF THE FOLLOWING MATRIX METALLOPROTEINASES: MMP-2, MMP-9, AND MMP-13, WHILE EXHIBITING SUBSTANTIALLY LESS INHIBITORY ACTIVITY AGAINST MMP-1 | G. D. SEARLE & COMPANY | 2002-09-10 | — | — | US | disclosed |
| EP-1157021-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2001-11-28 | — | — | EP | disclosed |
| WO-2000046221-A1 | SULFAMATO HYDROXAMIC ACID METALLOPROTEASE INHIBITOR | G.D. SEARLE & CO. (US) | 2000-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049280-A1 | Sulfamato hydroxamic acid metalloprotease inhibitor | MMP14, MMP12, MMP17 | ADRB2 4884/4885MMP13 23/4885MMP2 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.